Teleflex (NYSE:TFX) Releases FY 2026 Earnings Guidance

Teleflex (NYSE:TFX) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 6.250-6.550 for the period, compared to the consensus earnings per share estimate of 15.180. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $3.7 billion.

Teleflex Stock Down 0.3%

Teleflex stock opened at $111.83 on Thursday. The stock has a market capitalization of $4.94 billion, a price-to-earnings ratio of -15.21, a PEG ratio of 1.46 and a beta of 0.92. The company has a current ratio of 2.57, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67. The stock has a 50 day moving average of $111.44 and a two-hundred day moving average of $118.67. Teleflex has a twelve month low of $100.18 and a twelve month high of $178.79.

Analyst Ratings Changes

TFX has been the subject of a number of recent research reports. Truist Financial lifted their price target on shares of Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a report on Thursday, December 18th. Needham & Company LLC upgraded Teleflex from a “hold” rating to a “buy” rating and set a $138.00 target price for the company in a research note on Tuesday, January 27th. Wells Fargo & Company dropped their price objective on shares of Teleflex from $139.00 to $116.00 and set an “equal weight” rating for the company in a research note on Thursday, January 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $135.00 price target on shares of Teleflex in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Teleflex presently has an average rating of “Hold” and a consensus target price of $139.00.

Institutional Trading of Teleflex

Several large investors have recently added to or reduced their stakes in TFX. AQR Capital Management LLC boosted its holdings in Teleflex by 478.1% during the third quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company’s stock worth $287,603,000 after purchasing an additional 1,956,811 shares during the last quarter. State Street Corp grew its position in shares of Teleflex by 1.5% during the 4th quarter. State Street Corp now owns 1,478,776 shares of the medical technology company’s stock worth $180,470,000 after purchasing an additional 22,111 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Teleflex by 0.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,250,665 shares of the medical technology company’s stock valued at $152,630,000 after buying an additional 5,051 shares in the last quarter. Abrams Bison Investments LLC grew its position in Teleflex by 5.6% during the fourth quarter. Abrams Bison Investments LLC now owns 969,000 shares of the medical technology company’s stock worth $118,257,000 after buying an additional 51,075 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its stake in Teleflex by 21.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 696,950 shares of the medical technology company’s stock worth $85,056,000 after acquiring an additional 122,481 shares during the period. 95.62% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.